Showing 6831-6840 of 7455 results for "".
- Is 'Mitoiron Claw' the Next Great Sunscreen Ingredient?https://practicaldermatology.com/news/is-mitoiron-claw-the-next-great-sunscreen-ingredient/2458493/A new compound that blocks excess free iron in the mitochondria may offer dramatic protection against Ultraviolet A (UVA) radiation in sunlight, according to scientists at the University of Bath and King's College London. Most sunscreens protect well against solar Ultraviolet B
- CeraVe: Suncare Products Get Skin Cancer Foundation Seal of Recommendationhttps://practicaldermatology.com/news/cerave-suncare-products-get-skin-cancer-foundation-seal-of-recommendation/2458495/Two products from Valeant Consumer Healthcare's CeraVe skincare line have received The Skin Cancer Foundation (SCF) Seal of Recommendation for sunscreens. CeraVe® AM Facial Moisturizing Lotion with SPF 30 has earned the “Daily Use” Seal and CeraVe
- FDA Clears Syneron Candela's UltraShape Power for Fat Destructionhttps://practicaldermatology.com/news/fda-clears-syneron-candelas-ultrashape-power-for-fat-destruction/2458499/The FDA cleared Syneron Medical Ltd.'s non-invasive fat destruction device, UltraShape Power. for non-invasive reduction of abdominal circumference via fat cell destruction. UltraShape Power uses focused, pulsed mechanical ultrasound energy to target and destroy fat, offering measurab
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- New International Index Suggests Skin Cancer More Prevalent in Developed Countrieshttps://practicaldermatology.com/news/new-international-index-suggests-skin-cancer-more-prevalent-in-developed-countries/2458504/The USA has the 9th highest diagnoses of skin cancer per capita annually, according to a new report from Derma.plus. New Zealand had the most cases of skin cancer per capita followed by Australia, Switzerland, Sweden, and
- Topix Pharmaceuticals Partners with New Mountain Capitalhttps://practicaldermatology.com/news/new-mountain-capital-partners-with-topix-pharmaceuticals/2458505/Topix Pharmaceuticals, Inc. has partnered with New Mountain Capital, LLC, a growth-oriented investment firm that currently manages over $15 billion in assets. New Mountain, a New York-based private equity firm, identified Topix through a proactive focus in the life sciences and aestheti
- FDA Greenlights First-Ever OTC Retinoidhttps://practicaldermatology.com/news/fda-greenlights-first-ever-otc-retinoid/2458507/The U.S. Food and Drug Administration (FDA) approved Differin Gel 0.1% (adapalene), a once-daily topical gel for the over-the-counter (OTC) treatment of acne in people 12 years of age and older. Differin Gel 0.1% is the first retinoid to be made available OTC for the
- Sciton Launches New Program to Encourage Practice Growthhttps://practicaldermatology.com/news/sciton-launches-new-program-to-encourage-practice-growth/2458510/Sciton Inc. is unveiling their new practice support program. With Success Builder, Sciton offers four specialized pillars: clinical training, marketing tools, business development, and Sciton-sanctioned tools and courses. Many of the vendors also o
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme
- Daily ‘Soak and Smear' OKed for Kids with Eczemahttps://practicaldermatology.com/news/daily-soak-and-smear-oked-for-kids-with-eczema/2458513/Daily bathing is fine for children with eczema as long as it's followed by lots of moisturizer, according to a new article in Annals of Allergy, Asthma and Immunology. Researchers led by Portl